Warning letter
Deibel Laboratories of Illinois, Inc. [ARCHIVED]: warning letter of Sep 1, 2011
FDA warning letter 192913 · Chicago District Office
Key facts
| Reference number | 192913 |
|---|---|
| Company | Deibel Laboratories of Illinois, Inc. [ARCHIVED] |
| Subject | Current Good Manufacturing Practice for Finished Pharmaceuticals/Misbranded/Adulterated |
| Issue date | Sep 1, 2011 |
| Posted date | Sep 1, 2011 |
| Issuing office | Chicago District Office |
| Product type | Drugs |
| CFR sections cited | 211.165(b), 211.194(a)(2), 211.192, 211.194, 211.165(e), 211.160(a) |
| Inspection city | Lincolnwood |
| Inspection ZIP | 60712 |
| Inspection start date | Feb 23, 2011 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: